

Quant Keys

Costs as a style factor

Equities

Global
Quantitative

Expensive to trade stocks do not have a premium on a net returns basis

Expensive to trade stocks appear to outperform cheap to trade stocks (under some definitions of expensive to trade) on a gross return basis, but after costs have been introduced, the effect disappears in both Europe and the US. Only investors with unusually low costs or with very small portfolios would be able to take advantage of this effect. For most investors there is no premium, just higher costs.

Costs to trade appear to have declined

Using a well-known academic cost model we have estimated the costs to trade stocks. It appears that costs have fallen considerably over the last 20 years in Europe and the US, and larger trades are now much more feasible.

Claire Jones, CFA

Analyst

claire-c.jones@ubs.com
+44-20-7568 1873

David Jessop

Analyst


david.jessop@ubs.com
+44-20-7567 9882

Nick Baltas, PhD

Analyst

nick.baltas@ubs.com
+44-20-7568 3072

Figure 1: Costs appear to have fallen significantly over the last twenty years



Source: UBS Quantitative Research, Estimated cost to fully replicate the Dow Jones Europe index at different investment sizes, assuming all trades take place over the course of 1-day

Summary

Trading costs are hugely important to investors. We use a simple costs model (taken from Almgren et al, May 2005) to examine how costs have changed through time and whether there is a premium to expensive to trade stocks which would justify their greater expense.

Trading costs have fallen considerably since the 90s in Europe and in the US. The most marked change has been in bid-ask spreads, which have narrowed a great deal, making the direct costs an investor faces much lower. The proportion of a firm's shares outstanding traded on a typical day has also increased (although this figure has fallen over recent years) which means that price impact of trades has typically been lower.

Stocks which are more expensive to trade do not appear to be associated with higher net returns, not even for fairly small investment sizes, where the price impact of the trade is modest. It seems reasonable for investors to screen out the most expensive to trade names. This still appears to be true over the most recent five years when trading costs have been lower.

Costs model

We use a costs model taken from Almgren et al's paper *Direct Estimation of Equity Market Impact*, May 2005. They use five key inputs to estimate the cost of a trade:

- i. The **bid-ask spread (BA)**, a direct measure of charges made to the investor to buy or sell
- ii. **Volatility (σ)**, if the stock is more volatile, then the price is more likely to move during execution, which leads to higher costs
- iii. **Order size ($\frac{X}{V}$)** as a proportion of the average daily trading volume (ADV), larger orders tend to have bigger price impacts
- iv. Length of **time (T)** allowed to complete the order, if an investor demands faster execution he will need to pay more for the privilege
- v. The **inverse turnover ($\frac{\phi}{V}$)**, which is the inverse of the ADV as a proportion of the shares outstanding. There will typically be less price impact with more liquid companies

They divide the price impact into two categories, permanent and temporary, giving us this model:


Figure 2: Almgren et al's Cost Model

$$\begin{aligned} \text{Permanent price impact} &= 0.314 \cdot \sigma \cdot \frac{X}{V} \cdot \left(\frac{\phi}{V}\right)^{0.25} \\ \text{Temporary price impact} &= \frac{1}{2} \cdot \text{permanent price impact} + \text{sign}(X) \cdot 0.142 \cdot \sigma \cdot \left|\frac{X}{V \cdot T}\right|^{0.6} \\ \text{Direct costs} &= \frac{1}{2} \cdot BA \end{aligned}$$

Source: Almgren et al, *Direct Estimation of Equity Market Impact*, May 2005

If we input the data for a single stock we can see some key effects of this model. Below we have plotted how the cost of buying a stock varies with the size of the order, given an execution time of one day.

Figure 3: Example of how costs vary with order size



Source: UBS Quantitative Research, Data is for Tesco as of November 2014, estimates based on 1-day to execute the trade

Clearly the costs are convex: a larger order is more expensive in percentage terms (although this must eventually reach a maximum when you buy the whole company). Also the majority of costs are due to price impact, not the direct costs from the bid-ask spread.

Costs are convex and dominated by price impact

A word of caution though; Almgren et al's paper was published ten years ago, so their model may now be out of date - please take these costs as indicative only. That said however, we do not anticipate the sign of the relationships to have changed since Almgren et al's note's publication, so the broad direction of our conclusions should remain valid.

Also, after presenting this work at our London conference on March 26th several clients commented that the assumption of direct costs of half the bid-ask spread was overly pessimistic for their fund's execution costs. So, we have repeated some of our analysis assuming zero direct costs to examine how relevant our results are for clients who can obtain lower direct costs.

Our Data

Our main universe is the European stocks in the Dow Jones World Index. Our data history is from Mar-1996 to Nov-2014. We use Datastream data for our parameters to estimate the costs of trading for each stock back through time. For the sake of comparison, we have also considered the S&P 500 index from Dec-1992 to Feb-2015. For this US universe, we use CRSP data for our parameter data.

There are a few subtleties to be aware of:

- For our volatility estimates, we compute the volatility from the daily returns over the previous month's total returns.
- For the European bid-ask spreads and daily trading volumes we take the median over the course of the previous month to smooth out some data issues. For the US, we take data on the day.
- Share prices are taken at the close, in USD, for both universes.


Where we require European style portfolios for our analysis, we have taken the constituents and weights of the portfolios from our Global Style Watch definitions. Please see our latest edition (out on the first business day of the month) for a complete description, but in brief these portfolios are:

- Thirds of the universe e.g. low / mid / high earnings yield
- Region neutral (between UK and Europe ex UK) and broadly size neutral
- Cap weighted

How have costs changed over time?


The average bid-ask spread is a lot lower and turnover, a measure of liquidity showing the proportion of a firm's stocks outstanding traded on a typical day, has increased, although it has slipped back again since 2010. These suggest that costs have fallen.

Figure 4: Average bid-ask spread



Source: UBS Quantitative Research, Index weighted average of the largest 100 names in the European index on that date

Figure 5: Average turnover




Source: UBS Quantitative Research, Index weighted average of the largest 100 names in the European index on that date

If we input each stock's historical parameters into our simple costs model then we can get a rough estimate of the cost to buy or sell different amounts of each stock. Using all of this historical data, we can estimate the costs of fully replicating the index, in one day, with different investment amounts (e.g. \$100,000). This is shown in Figure 6.

We deflate the \$-investment back through time by CPI, so that all investment amounts are in 2015 money. We cap the amount we can buy in any one stock at 30% of its average daily volume (ADV) and leave any remnant not invested. If this leads to less than 95% of the investment invested then we don't plot a point for that date and investment size e.g. pre 2005 it was not feasible to buy \$1bn of the index in one day without breaching the 30% of ADV bound on a large numbers of stocks.

Figure 6: In Europe, costs have fallen significantly over the last twenty years



Source: UBS Quantitative Research, Estimated cost to fully replicate the index at different investment sizes

Costs appear to have fallen significantly. Also it is now possible to buy larger amounts of the index over short periods than it was historically, so in that sense the market appears to be more liquid.

It is much cheaper to trade in Europe than it has been historically


Looking at the estimated cost to buy \$100,000 in a day, where the price impact is a fairly minor part of the costs, we can see that most of the changing cost seems to have come from declining bid-ask spreads. However, as you can see from the tightening of the gap between the lines for different investment values, the price impact also appears to have fallen as markets become more liquid.

If we repeat this analysis in the US, looking at the cost to fully replicate the S&P 500, we see a similar pattern (although with much noisier data). Figure 7 illustrates this. Costs have fallen dramatically since 1992, when our data begins, and has continued to gradually decline since 2005, although with higher costs through the recent financial crisis.

Similar pattern in the US

The US appears to have been a more liquid market than Europe historically. It seems that, even in the early 90s it would have been possible to buy \$100 million worth of the S&P 500 in a single day, albeit with high trading costs. The current cost to fully replicate the S&P 500 is somewhat lower than the current cost to replicate the European index.

Figure 7: Cost to trade the S&P 500



Source: UBS Quantitative Research, Estimated cost to fully replicate the S&P 500 index at different investment sizes

How effective is cost-to-trade as a style?

You might anticipate that, as an undesirable trait, investors would be compensated for holding stocks which are more expensive to trade in to and out of. We do not see strong evidence of this.


We consider two definitions of cost-to-trade:

Two definitions of cost-to-trade

- \$-based definition**, we rank our universe based on how much would it cost to buy \$500,000 worth of the stock in one day.
- Volume-based definition**, we rank our stocks based on how much it would cost to buy 10% of the average daily volume.

For each definition, we start by dividing the universe into two sub-portfolios: cheap-to-trade and expensive-to-trade. We weight the stocks in each sub-portfolio in proportion to its weight in the overall index, and rebalance the portfolio at the end of each month. We simulate the historical returns to these two portfolios over the period from Mar-1996 to Nov-2014. We find the return either without costs, or net of estimated costs assuming our investment of a particular size on our starting date.

Figure 8: \$-based Definition - Is there are premium on expensive to trade stocks?




Source: UBS Quantitative Research, European universe

The \$-based definition has an obvious bias towards small-caps. For small-cap firms \$0.5m may represent a substantial share of their total market cap, so it is likely to be an expensive trade. We know there is a probably small-cap premium, so it is perhaps not surprising that, with small investments, there is a premium to expensive to trade stocks under the \$-based definition. At an initial investment of \$100,000 the expensive to trade portfolio outperforms, with an annualised net return of 10.9% compared to 7.6% for the cheap to trade portfolio. However, with larger investments costs soon take their toll. By \$10m, cheap to trade is outperforming expensive to trade.

\$-based definition – premium to expensive-to-trade stocks rapidly eaten away by costs

In the US universe we see a similar pattern. Figure 9 shows the net return to the cheap to trade and expensive to trade S&P 500 portfolios over the last 5 years. Without costs we can see a premium of around 3.3% per annum, but the higher costs in the expensive to trade basket rapidly erode that difference.


Figure 9: \$-based Definition – What happens in the US?



Source: UBS Quantitative Research, US universe

Returning to the European analysis, but this time assuming zero direct costs by setting the bid-ask spread to zero, the premium to expensive to trade stocks persists for higher investment sizes. The performance of the cheap to trade portfolio and expensive to trade portfolios equalise when the investment size is \$100m per day, not \$10m, although for an investment size of \$1bn the cheap-to-trade portfolio outperforms strongly.

Figure 10: Volume-based Definition - Is there are premium on expensive to trade stocks?



Source: UBS Quantitative Research, European universe

With the volume-based definition we don't see any premium to the expensive to trade portfolio – just higher costs. Even for the portfolio return assuming no costs we see very little difference between the cheap to trade and expensive to trade portfolios. Once we introduce costs the return to the expensive to trade portfolio falls off very rapidly, while the impact on the cheap to trade portfolio is more gradual. It appears that screening out these expensive to trade names would be advantageous for investors.

Volume-based definition – no premium to expensive-to-trade

If we tweak our costs model and assume that investors have no direct costs to trade (i.e. set the bid-ask spread is zero) this result does not change. It appears that all investors, even those who face lower execution costs than the average, could gain from screening out these expensive to trade names.

If we repeat this analysis just over the last five years, in the new, lower cost environment our results are similar.

What about at the style level?


The analysis above is all at the benchmark level, but if we look at the style level we see a very similar picture.

For each style portfolio e.g. high ROIC or low earnings momentum, we divided the portfolio into two sub-portfolios based on the cost to trade. We then simulated the performance of these sub-portfolios from Mar-96 to Nov-14 and computed the returns either without costs or with costs based on various investment sizes.

We have plotted our results for the \$-based definition in Figure 11. The x-axis is qualitative and represents the style portfolios (e.g. high ROIC). It has been ordered by return to the cheap-to-trade sub-portfolio without costs. The red dots represent the return to a cheap-to-trade sub-portfolio and the blue dots the return to an expensive-to-trade sub-portfolio.

Even at the style level, expensive-to-trade stocks tends to underperform on a net return basis with larger portfolios

Figure 11: \$-based Definition – is there an expensive to trade premium in some style portfolios?



Source: UBS Quantitative Research, European universe

Without costs the expensive-to-trade sub-portfolios almost all outperform their cheap-to-trade counterparts. However, once we include even quite modest costs increasing numbers of the expensive-to-trade sub-portfolios underperform. By the time we are dealing with costs associated with a portfolio of around \$10m, the majority of the cheap-to-trade sub-portfolios outperform.

Can we just exclude the expensive to trade stocks?


Excluding stocks from your portfolio will naturally lead to more concentrated portfolios, which leads to larger positions and thus more expensive trades (as costs are convex). We need to ensure that excluding the expensive-to-trade stocks doesn't increase costs by leading to more concentrated portfolios. Fortunately this doesn't seem to be a serious problem, as Figure 12 illustrates.

Yes - excluding the expensive to trades stocks reduces costs, and this effect is not offset by increasingly concentrated portfolios

We take our data for the stocks in the index as of Nov-14 and sort it from least to most expensive to trade (based on estimated costs of buying \$0.5m in a day). We then estimate the costs of buying an investment amount (e.g. \$100,000) in the cheapest N-many stocks in one day. Once we have multiple stocks in the portfolio we weight each stock proportional to their weights in the index overall.

We have plotted the number of stocks vs the estimated cost to trade for various investment sizes in the figure, and labelled the minimum point. For example, if you wish to buy \$100m in one day it is cheapest to do this with a portfolio of the 109 cheapest to trade stocks, although anywhere from 68 to 299 stocks gets an overall cost to trade of less than 3 basis points.

Figure 12: Can we exclude expensive to trade stocks without increasing costs? Yes



Source: UBS Quantitative Research

There is a balance to be struck between holding exclusively very cheap to trade stocks (and hence holding a more concentrated portfolio), and holding some more expensive to trade stocks. From this empirical work though, screening out the most expensive to trade stocks (even as much as half the universe) does appear to reduce costs.

Conclusions

Based on the Almgren et al costs model it appears that the cost to trade has fallen dramatically over the last twenty years. It is now feasible to make larger trades, faster without moving the market excessively.

After we have accounted for costs, there does not appear to be any premium to holding expensive-to-trade stocks, except for small investments. So, in the absence of any compelling case for a stock, it would seem to be advantageous to exclude these expensive-to-trade stocks from our portfolios, even though this will lead to more concentrated portfolios.

UBS Equity Quantitative Research publications

Monographs

	Title	Date
	Cross-Asset Seasonality	Mar-15
	Extending our quality model to financials	Mar-15
	Where are the crowded trades?	Jan-15
	Stock Selection using Machine Learning	Jan-15
	Investing in Growth	Jan-15
	Harvesting Cross-Asset Value	Dec-14
	How to avoid 'Torpedoes'	Nov-14
	US Quantitative Conference Highlights	Nov-14
	What happens when volatility normalises?	Oct-14
	Watch out for macro risk: the impact on China H- and A-share markets	Oct-14
	Three key questions on low volatility	Oct-14
	Trading around M&A announcements in the US	Sep-14
	Investing in Value	Sep-14
	How to avoid 'torpedoes' in Asia	Jul-14
	Correlation, De-correlation and Risk-Parity	Jun-14
	Risk-Parity versus Mean-Variance	May-14
	Timing the US earnings yield style	May-14
	Investing in Quality	Apr-14
	How Asian stocks trade after earnings surprises	Mar-14
	From forecasts to portfolios	Jan-14
	Three reasons why high-risk underperformed	Dec-13
	Trend following meets risk parity	Dec-13

PAS User Guides

	Introduction to the UBS Portfolio Analysis System	Jan-15
	Advanced Analysis	Oct-12
	Installation	May-14
	Long-Short Analysis	Jan-15
	Optimisation with PAS	Jun-10
	PAS Macros	Nov-11
	Quick Reference Guide	Jun-10

Academic Research Monitor

	Topic	Date
	UBS Quantitative Conference Highlights	Apr-15
	Smart Beta, Factors and Style Investing	Feb-15
	Momentum-Investing	Jan-15
	Investment Strategies & Textual Analysis Signals	Dec-14
	Commodity Risk & Institutional Investing Habits	Nov-14
	Index Membership, Investor (in)attention to News & Spurious Correlations	Sep-14
	Forecasting the Equity Risk Premium	Aug-14
	Implied Cost of Capital & Shorting Premium	Jun-14
	European Quantitative Conference Highlights	May-14
	Trend Following	Mar-14
	Factor investing & Quality	Feb-14
	Quality & Gross Profitability	Jan-14
	Minimum variance: valuation, concentration and exchange rates	Dec-13
	Liquidity & back test overfitting	Oct-13
	News and its effect on asset prices	Sep-13
	Asset pricing & skewness	Aug-13
	Timing momentum & risk parity	Jul-13

Statement of Risk

Each research analyst primarily responsible for the content of this research report, in whole or in part, certifies that with respect to each security or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about those securities or issuers and were prepared in an independent manner, including with respect to UBS, and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in the research report.

Required Disclosures

This report has been prepared by UBS Limited, an affiliate of UBS AG. UBS AG, its subsidiaries, branches and affiliates are referred to herein as UBS.

For information on the ways in which UBS manages conflicts and maintains independence of its research product; historical performance information; and certain additional disclosures concerning UBS research recommendations, please visit www.ubs.com/disclosures. The figures contained in performance charts refer to the past; past performance is not a reliable indicator of future results. Additional information will be made available upon request. UBS Securities Co. Limited is licensed to conduct securities investment consultancy businesses by the China Securities Regulatory Commission.

Analyst Certification: Each research analyst primarily responsible for the content of this research report, in whole or in part, certifies that with respect to each security or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about those securities or issuers and were prepared in an independent manner, including with respect to UBS, and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in the research report.

UBS Investment Research: Global Equity Rating Definitions

12-Month Rating	Definition	Coverage ¹	IB Services ²
Buy	FSR is > 6% above the MRA.	45%	37%
Neutral	FSR is between -6% and 6% of the MRA.	43%	33%
Sell	FSR is > 6% below the MRA.	12%	20%
Short-Term Rating	Definition	Coverage ³	IB Services ⁴
Buy	Stock price expected to rise within three months from the time the rating was assigned because of a specific catalyst or event.	less than 1%	less than 1%
Sell	Stock price expected to fall within three months from the time the rating was assigned because of a specific catalyst or event.	less than 1%	less than 1%

Source: UBS. Rating allocations are as of 31 March 2015.

1:Percentage of companies under coverage globally within the 12-month rating category. 2:Percentage of companies within the 12-month rating category for which investment banking (IB) services were provided within the past 12 months.

3:Percentage of companies under coverage globally within the Short-Term rating category. 4:Percentage of companies within the Short-Term rating category for which investment banking (IB) services were provided within the past 12 months.

KEY DEFINITIONS: **Forecast Stock Return (FSR)** is defined as expected percentage price appreciation plus gross dividend yield over the next 12 months. **Market Return Assumption (MRA)** is defined as the one-year local market interest rate plus 5% (a proxy for, and not a forecast of, the equity risk premium). **Under Review (UR)** Stocks may be flagged as UR by the analyst, indicating that the stock's price target and/or rating are subject to possible change in the near term, usually in response to an event that may affect the investment case or valuation. **Short-Term Ratings** reflect the expected near-term (up to three months) performance of the stock and do not reflect any change in the fundamental view or investment case. **Equity Price Targets** have an investment horizon of 12 months.

EXCEPTIONS AND SPECIAL CASES: **UK and European Investment Fund ratings and definitions are:** **Buy:** Positive on factors such as structure, management, performance record, discount; **Neutral:** Neutral on factors such as structure, management, performance record, discount; **Sell:** Negative on factors such as structure, management, performance record, discount. **Core Banding Exceptions (CBE):** Exceptions to the standard +/-6% bands may be granted by the Investment Review Committee (IRC). Factors considered by the IRC include the stock's volatility and the credit spread of the respective company's debt. As a result, stocks deemed to be very high or low risk may be subject to higher or lower bands as they relate to the rating. When such exceptions apply, they will be identified in the Company Disclosures table in the relevant research piece.

Research analysts contributing to this report who are employed by any non-US affiliate of UBS Securities LLC are not registered/qualified as research analysts with the NASD and NYSE and therefore are not subject to the restrictions contained in the NASD and NYSE rules on communications with a subject company, public appearances, and trading securities held by a research analyst account. The name of each affiliate and analyst employed by that affiliate contributing to this report, if any, follows.

UBS Limited: Claire Jones, CFA; David Jessop; Nick Baltas, PhD.

Unless otherwise indicated, please refer to the Valuation and Risk sections within the body of this report.

Global Disclaimer

This document has been prepared by UBS Limited, an affiliate of UBS AG. UBS AG, its subsidiaries, branches and affiliates are referred to herein as UBS.

Global Research is provided to our clients through UBS Neo, the UBS Client Portal and UBS.com (each a "System"). It may also be made available through third party vendors and distributed by UBS and/or third parties via e-mail or alternative electronic means. The level and types of services provided by Global Research to a client may vary depending upon various factors such as a client's individual preferences as to the frequency and manner of receiving communications, a client's risk profile and investment focus and perspective (e.g. market wide, sector specific, long-term, short-term, etc.), the size and scope of the overall client relationship with UBS and legal and regulatory constraints.

When you receive Global Research through a System, your access and/or use of such Global Research is subject to this Global Research Disclaimer and to the terms of use governing the applicable System.

When you receive Global Research via a third party vendor, e-mail or other electronic means, your use shall be subject to this Global Research Disclaimer and to UBS's Terms of Use/Disclaimer (<http://www.ubs.com/global/en/legalinfo2/disclaimer.html>). By accessing and/or using Global Research in this manner, you are indicating that you have read and agree to be bound by our Terms of Use/Disclaimer. In addition, you consent to UBS processing your personal data and using cookies in accordance with our Privacy Statement (<http://www.ubs.com/global/en/legalinfo2/privacy.html>) and cookie notice (<http://www.ubs.com/global/en/homepage/cookies/cookie-management.html>).

If you receive Global Research, whether through a System or by any other means, you agree that you shall not copy, revise, amend, create a derivative work, transfer to any third party, or in any way commercially exploit any UBS research provided via Global Research or otherwise, and that you shall not extract data from any research or estimates provided to you via Global Research or otherwise, without the prior written consent of UBS.

For access to all available Global Research on UBS Neo and the Client Portal, please contact your UBS sales representative.

This document is for distribution only as may be permitted by law. It is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or would subject UBS to any registration or licensing requirement within such jurisdiction. It is published solely for information purposes; it is not an advertisement nor is it a solicitation or an offer to buy or sell any financial instruments or to participate in any particular trading strategy. No representation or warranty, either expressed or implied, is provided in relation to the accuracy, completeness or reliability of the information contained in this document ("the Information"), except with respect to Information concerning UBS. The Information is not intended to be a complete statement or summary of the securities, markets or developments referred to in the document. UBS does not undertake to update or keep current the Information. Any opinions expressed in this document may change without notice and may differ or be contrary to opinions expressed by other business areas or groups of UBS. Any statements contained in this report attributed to a third party represent UBS's interpretation of the data, information and/or opinions provided by that third party either publicly or through a subscription service, and such use and interpretation have not been reviewed by the third party.

Nothing in this document constitutes a representation that any investment strategy or recommendation is suitable or appropriate to an investor's individual circumstances or otherwise constitutes a personal recommendation. Investments involve risks, and investors should exercise prudence and their own judgement in making their investment decisions. The financial instruments described in the document may not be eligible for sale in all jurisdictions or to certain categories of investors. Options, derivative products and futures are not suitable for all investors, and trading in these instruments is considered risky. Mortgage and asset-backed securities may involve a high degree of risk and may be highly volatile in response to fluctuations in interest rates or other market conditions. Foreign currency rates of exchange may adversely affect the value, price or income of any security or related instrument referred to in the document. For investment advice, trade execution or other enquiries, clients should contact their local sales representative.

The value of any investment or income may go down as well as up, and investors may not get back the full (or any) amount invested. Past performance is not necessarily a guide to future performance. Neither UBS nor any of its directors, employees or agents accepts any liability for any loss (including investment loss) or damage arising out of the use of all or any of the Information.

Any prices stated in this document are for information purposes only and do not represent valuations for individual securities or other financial instruments. There is no representation that any transaction can or could have been effected at those prices, and any prices do not necessarily reflect UBS's internal books and records or theoretical model-based valuations and may be based on certain assumptions. Different assumptions by UBS or any other source may yield substantially different results.

This document and the Information are produced by UBS as part of its research function and are provided to you solely for general background information. UBS has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient. In no circumstances may this document or any of the Information be used for any of the following purposes:

- (i) valuation or accounting purposes;
- (ii) to determine the amounts due or payable, the price or the value of any financial instrument or financial contract; or
- (iii) to measure the performance of any financial instrument.

By receiving this document and the Information you will be deemed to represent and warrant to UBS that you will not use this document or any of the Information for any of the above purposes or otherwise rely upon this document or any of the Information.

Research will initiate, update and cease coverage solely at the discretion of UBS Investment Bank Research Management. The analysis contained in this document is based on numerous assumptions. Different assumptions could result in materially different results. The analyst(s) responsible for the preparation of this document may interact with trading desk personnel, sales personnel and other parties for the purpose of gathering, applying and interpreting market information. UBS relies on information barriers to control the flow of information contained in one or more areas within UBS into other areas, units, groups or affiliates of UBS. The compensation of the analyst who prepared this document is determined exclusively by research management and senior management (not including investment banking). Analyst compensation is not based on investment banking revenues; however, compensation may relate to the revenues of UBS Investment Bank as a whole, of which investment banking, sales and trading are a part.

For financial instruments admitted to trading on an EU regulated market: UBS AG, its affiliates or subsidiaries (excluding UBS Securities LLC) acts as a market maker or liquidity provider (in accordance with the interpretation of these terms in the UK) in the financial instruments of the issuer save that where the activity of liquidity provider is carried out in accordance with the definition given to it by the laws and regulations of any other EU jurisdictions, such information is separately disclosed in this document. For financial instruments admitted to trading on a non-EU regulated market: UBS may act as a market maker save that where this activity is carried out in the US in accordance with the definition given to it by the relevant laws and regulations, such activity will be specifically disclosed in this document. UBS may have issued a warrant the value of which is based on one or more of the financial instruments referred to in the document. UBS and its affiliates and employees may have long or short positions, trade as principal and buy and sell in instruments or derivatives identified herein; such transactions or positions may be inconsistent with the opinions expressed in this document.

United Kingdom and the rest of Europe: Except as otherwise specified herein, this material is distributed by UBS Limited to persons who are eligible counterparties or professional clients. UBS Limited is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority. **France:** Prepared by UBS Limited and distributed by UBS Limited and UBS Securities France S.A. UBS Securities France S.A. is regulated by the ACPR (Autorité de Contrôle Prudentiel et de Résolution) and the Autorité des Marchés Financiers (AMF). Where an analyst of UBS Securities France S.A. has contributed to this document, the document is also deemed to have been prepared by UBS Securities France S.A. **Germany:** Prepared by UBS Limited and distributed by UBS Limited and UBS Deutschland AG. UBS Deutschland AG is regulated by the Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin). **Spain:** Prepared by UBS Limited and distributed by UBS Limited and UBS Securities España SV, SA. UBS Securities España SV, SA is regulated by the Comisión Nacional del Mercado de Valores (CNMV). **Turkey:** Distributed by UBS Limited. No information in this document is provided for the purpose of offering, marketing and sale by any means of any capital market instruments and services in the Republic of Turkey. Therefore, this document may not be considered as an offer made or to be made to residents of the Republic of Turkey. UBS AG is not licensed by the Turkish Capital Market Board under the provisions of the Capital Market Law (Law No. 6362). Accordingly, neither this document nor any other offering material related to the instruments/services may be utilized in connection with providing any capital market services to persons within the Republic of Turkey without the prior approval of the Capital Market Board. However, according to article 15 (d) (ii) of the Decree No. 32, there is no restriction on the purchase or sale of the securities abroad by residents of the Republic of Turkey. **Poland:** Distributed by UBS Limited (spółka z ograniczoną odpowiedzialnością) Oddział w Polsce regulated by the Polish Financial Supervision Authority. Where an analyst of UBS Limited (spółka z ograniczoną odpowiedzialnością) Oddział w Polsce has contributed to this document, the document is also deemed to have been prepared by UBS Limited (spółka z ograniczoną odpowiedzialnością) Oddział w Polsce. **Russia:** Prepared and distributed by UBS Bank (OOO). **Switzerland:** Distributed by UBS AG to persons who are institutional investors only. UBS AG is regulated by the Swiss Financial Market Supervisory Authority (FINMA). **Italy:** Prepared by UBS Limited and distributed by UBS Limited and UBS Italia Sim S.p.A. UBS Italia Sim S.p.A. is regulated by the Bank of Italy and by the Commissione Nazionale per le Società e la Borsa (CONSOB). Where an analyst of UBS Italia Sim S.p.A. has contributed to this document, the document is also deemed to have been prepared by UBS Italia Sim S.p.A. **South Africa:** Distributed by UBS South Africa (Pty) Limited (Registration No. 1995/011140/07), an authorised user of the JSE and an authorised Financial Services Provider (FSP 7328). **Israel:** This material is distributed by UBS Limited. UBS Limited is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority. UBS Securities Israel Ltd is a licensed Investment Marketer that is supervised by the Israel Securities Authority (ISA). UBS Limited and its affiliates incorporated outside Israel are not licensed under the Israeli Advisory Law. UBS Limited is not covered by insurance as required from a licensee under the Israeli Advisory Law. UBS may engage among others in issuance of Financial Assets or in distribution of Financial Assets of other issuers for fees or other benefits. UBS Limited and its affiliates may prefer various Financial Assets to which they have or may have Affiliation (as such term is defined under the Israeli Advisory Law). Nothing in this Material should be considered as investment advice under the Israeli Advisory Law. This Material is being issued only to and/or is directed only at persons who are Eligible Clients within the meaning of the Israeli Advisory Law, and this material must not be relied on or acted upon by any other persons. **Saudi Arabia:** This document has been issued by UBS AG (and/or any of its subsidiaries, branches or affiliates), a public company limited by shares, incorporated in Switzerland with its registered offices at Aeschenvorstadt 1, CH-4051 Basel and Bahnhofstrasse 45, CH-8001 Zurich. This publication has been approved by UBS Saudi Arabia (a subsidiary of UBS AG), a Saudi closed joint stock company incorporated in the Kingdom of Saudi Arabia under commercial register number 1010257812 having its registered office at Tatweer Towers, P.O. Box 75724, Riyadh 11588, Kingdom of Saudi Arabia. UBS Saudi Arabia is authorized and regulated by the Capital Market Authority to conduct securities business under license number 08113-37. **Dubai:** The information distributed by UBS AG Dubai Branch is intended for Professional Clients only and is not for further distribution within the United Arab Emirates. **United States:** Distributed to US persons by either UBS Securities LLC or by UBS Financial Services Inc., subsidiaries of UBS AG; or by a group, subsidiary or affiliate of UBS AG that is not registered as a US broker-dealer (a 'non-US affiliate') to major US institutional investors only. UBS Securities LLC or UBS Financial Services Inc. accepts responsibility for the content of a document prepared by another non-US affiliate when distributed to US persons by UBS Securities LLC or UBS Financial Services Inc. All transactions by a US person in the securities mentioned in this document must be effected through UBS Securities LLC or UBS Financial Services Inc., and not through a non-US affiliate. **Canada:** Distributed by UBS Securities Canada Inc., a registered investment dealer in Canada and a Member-Canadian Investor Protection Fund, or by another affiliate of UBS AG that is registered to conduct business in Canada or is otherwise exempt from registration. **Brazil:** Except as otherwise specified herein, this material is prepared by UBS Brasil CCTVM S.A. to persons who are eligible investors residing in Brazil, which are considered to be: (i) financial institutions, (ii) insurance firms and investment capital companies, (iii) supplementary pension entities, (iv) entities that hold financial investments higher than R\$300,000.00 and that confirm the status of qualified investors in written, (v) investment funds, (vi) securities portfolio managers and securities consultants duly authorized by Comissão de Valores Mobiliários (CVM), regarding their own investments, and (vii) social security systems created by the Federal Government, States, and Municipalities. **Hong Kong:** Distributed by UBS Securities Asia Limited and/or UBS AG, Hong Kong Branch. **Singapore:** Distributed by UBS Securities Pte. Ltd. [MCI (P) 016/09/2014 and Co. Reg. No.: 198500648C] or UBS AG, Singapore Branch. Please contact UBS Securities Pte. Ltd., an exempt financial adviser under the Singapore Financial Advisers Act (Cap. 110); or UBS AG, Singapore Branch, an exempt financial adviser under the Singapore Financial Advisers Act (Cap. 110) and a wholesale bank licensed under the Singapore Banking Act (Cap. 19) regulated by the Monetary Authority of Singapore, in respect of any matters arising from, or in connection with, the analysis or document. The recipients of this document represent and warrant that they are accredited and institutional investors as defined in the Securities and Futures Act (Cap. 289). **Japan:** Distributed by UBS Securities Japan Co., Ltd. to professional investors (except as otherwise permitted). Where this document has been prepared by UBS Securities Japan Co., Ltd., UBS Securities Japan Co., Ltd. is the author, publisher and distributor of the document. Distributed by UBS AG, Tokyo Branch to Professional Investors (except as otherwise permitted) in relation to foreign exchange and other banking businesses when relevant. **Australia:** Clients of UBS AG: Distributed by UBS AG (Holder of Australian Financial Services License No. 231087). Clients of UBS Securities Australia Ltd: Distributed by UBS Securities Australia Ltd (Holder of Australian Financial Services License No. 231098). Clients of UBS Wealth Management Australia Ltd: Distributed by UBS Wealth Management Australia Ltd (Holder of Australian Financial Services License No. 231127). This Document contains general information and/or general advice only and does not constitute personal financial product advice. As such, the Information in this document has been prepared without taking into account any investor's objectives, financial situation or needs, and investors should, before acting on the Information, consider the appropriateness of the Information, having regard to their objectives, financial situation and needs. If the Information contained in this document relates to the acquisition, or potential acquisition of a particular financial product by a 'Retail' client as defined by section 761G of the Corporations Act 2001 where a Product Disclosure Statement would be required, the retail client should obtain and consider the Product Disclosure Statement relating to the product before making any decision about whether to acquire the product. The UBS Securities Australia Limited Financial Services Guide is available at: www.ubs.com/ecs-research-fsg. **New Zealand:** Distributed by UBS New Zealand Ltd. The information and recommendations in this publication are provided for general information purposes only. To the extent that any such information or recommendations constitute financial advice, they do not take into account any person's particular financial situation or goals. We recommend that recipients seek advice specific to their circumstances from their financial advisor. **Korea:** Distributed in Korea by UBS Securities Pte. Ltd., Seoul Branch. This document may have been edited or contributed to from time to time by affiliates of UBS Securities Pte. Ltd., Seoul Branch. **Malaysia:** This material is authorized to be distributed in Malaysia by UBS Securities Malaysia Sdn. Bhd (Capital Markets Services License No.: CMSL/A0063/2007). This material is intended for professional/institutional clients only and not for distribution to any retail clients. **India:** Prepared by UBS Securities India Private Ltd. (Corporate Identity Number U67120MH1996PTC097299) 2/F, 2 North Avenue, Maker Maxity, Bandra Kurla Complex, Bandra (East), Mumbai (India) 400051. Phone: +912261556000 SEBI Registration Numbers: NSE (Capital Market Segment): INB230951431, NSE (F&O Segment) INF230951431, BSE (Capital Market Segment) INB010951437.

The disclosures contained in research documents produced by UBS Limited shall be governed by and construed in accordance with English law.

UBS specifically prohibits the redistribution of this document in whole or in part without the written permission of UBS and UBS accepts no liability whatsoever for the actions of third parties in this respect. Images may depict objects or elements that are protected by third party copyright, trademarks and other intellectual property rights. © UBS 2015. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.

